MX9308025A - Compuestos inhibidores de la proteasa del virus dela inmunodeficiencia humana, procedimiento para supreparacion y formulacion farmaceutica que los contiene. - Google Patents

Compuestos inhibidores de la proteasa del virus dela inmunodeficiencia humana, procedimiento para supreparacion y formulacion farmaceutica que los contiene.

Info

Publication number
MX9308025A
MX9308025A MX9308025A MX9308025A MX9308025A MX 9308025 A MX9308025 A MX 9308025A MX 9308025 A MX9308025 A MX 9308025A MX 9308025 A MX9308025 A MX 9308025A MX 9308025 A MX9308025 A MX 9308025A
Authority
MX
Mexico
Prior art keywords
supreparation
procedure
pharmaceutical formulation
immunodeficiency virus
human immunodeficiency
Prior art date
Application number
MX9308025A
Other languages
English (en)
Inventor
Bruce Anthony Dressman
Marlys Hammond
Stephen Warren Kaldor
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX9308025A publication Critical patent/MX9308025A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C07D215/60—N-oxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona nuevos inhibidores de proteasa de HIV, formulaciones farmacéuticas que contienen estos compuestos y procedimientos de tratamiento y/o prevención de infección por HIV y/o Sida.
MX9308025A 1992-12-22 1993-12-15 Compuestos inhibidores de la proteasa del virus dela inmunodeficiencia humana, procedimiento para supreparacion y formulacion farmaceutica que los contiene. MX9308025A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99562192A 1992-12-22 1992-12-22

Publications (1)

Publication Number Publication Date
MX9308025A true MX9308025A (es) 1994-08-31

Family

ID=25542022

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9308025A MX9308025A (es) 1992-12-22 1993-12-15 Compuestos inhibidores de la proteasa del virus dela inmunodeficiencia humana, procedimiento para supreparacion y formulacion farmaceutica que los contiene.

Country Status (15)

Country Link
EP (1) EP0609625A1 (es)
JP (1) JPH06256277A (es)
KR (1) KR940014336A (es)
CN (1) CN1092410A (es)
AU (1) AU5252993A (es)
BR (1) BR9305161A (es)
CA (1) CA2112052A1 (es)
CO (1) CO4180513A1 (es)
CZ (1) CZ281393A3 (es)
FI (1) FI935780A7 (es)
HU (1) HUT69703A (es)
IL (1) IL108098A0 (es)
MX (1) MX9308025A (es)
NO (1) NO934721L (es)
PL (1) PL301578A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5747540A (en) * 1996-10-21 1998-05-05 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
DE60124080T2 (de) 2000-03-23 2007-03-01 Elan Pharmaceuticals, Inc., San Francisco Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
US6846813B2 (en) 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
EP1666452A2 (en) 2000-06-30 2006-06-07 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
WO2002002506A2 (en) 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
IL154993A0 (en) * 2000-09-29 2003-10-31 Neurogen Corp High affinity small molecule c5a receptor modulators
BR0210721A (pt) 2001-06-27 2004-07-20 Elan Pharm Inc Composto, sal ou éster farmaceuticamente aceitável, método para fabricar um composto, e, método para tratar um paciente que tem, ou para evitar que o paciente adquira uma doença ou condição
CA2454059A1 (en) * 2001-07-19 2003-01-30 Cv Therapeutics, Inc. Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
AU2002343483A1 (en) 2001-10-04 2003-04-14 Elan Pharmaceuticals, Inc. Hydroxypropylamines
WO2004058686A1 (en) 2002-04-30 2004-07-15 Elan Pharmaceuticals, Inc. Hydroxypropyl amides for the treatment of alzheimer’s disease
JP4698991B2 (ja) * 2004-09-14 2011-06-08 日本曹達株式会社 ピリジルメチルカルバミン酸エステル化合物、その製造方法及びピリジルメチルアミン化合物の製造方法
JP4721214B2 (ja) * 2004-09-14 2011-07-13 日本曹達株式会社 ピリジルメチルカルバミン酸エステル化合物及びピリジルメチルアミン化合物の製造方法
NZ562314A (en) 2005-04-08 2010-02-26 Comentis Inc Compounds which inhibit beta-secretase activity and methods of use thereof
WO2010002994A1 (en) 2008-07-01 2010-01-07 Purdue Research Foundation Nonpeptide hiv-1 protease inhibitors
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
CN110872251A (zh) * 2019-11-28 2020-03-10 卡博金艾美斯医药(上海)有限公司 N-乙基吡啶甲胺三氟乙酸盐及其晶体、制备工艺和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0361341A3 (en) * 1988-09-28 1991-07-03 Miles Inc. Therapeutics for aids based on inhibitors of hiv protease
WO1991008221A1 (en) * 1989-12-04 1991-06-13 Wisconsin Alumni Research Foundation Peptide inhibitors of hiv protease
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives

Also Published As

Publication number Publication date
CZ281393A3 (en) 1994-07-13
KR940014336A (ko) 1994-07-18
IL108098A0 (en) 1994-04-12
AU5252993A (en) 1994-07-07
BR9305161A (pt) 1994-11-01
FI935780A0 (fi) 1993-12-21
FI935780A7 (fi) 1994-06-23
JPH06256277A (ja) 1994-09-13
PL301578A1 (en) 1994-06-27
CO4180513A1 (es) 1995-06-07
EP0609625A1 (en) 1994-08-10
CN1092410A (zh) 1994-09-21
NO934721D0 (no) 1993-12-20
NO934721L (no) 1994-06-23
CA2112052A1 (en) 1994-06-23
HUT69703A (en) 1995-09-28
HU9303677D0 (en) 1994-04-28

Similar Documents

Publication Publication Date Title
MX9308016A (es) Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene.
MX9308025A (es) Compuestos inhibidores de la proteasa del virus dela inmunodeficiencia humana, procedimiento para supreparacion y formulacion farmaceutica que los contiene.
MX9308005A (es) Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene.
ES2150933T3 (es) Inhibidores de la proteasa vih utiles para el tratamiento del sida.
MX9308010A (es) Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene.
MX9204454A (es) Derivados de tiourea para inhibir la replicacion del virus de inmunodeficiencia humana y formulado farmaceutico que los contiene.
MX9403380A (es) Inhibidores de proteasa de vih utiles para el tratamiento de sida.
MX9303263A (es) Antagonistas de la angiotensina ii, procedimiento para su preparacion y formulaciones farmaceuticas que los contienen
BG100455A (en) Hiv protease inhibitors
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
ES2125251T3 (es) Inhibidores de la proteasa del vih.
ATE298741T1 (de) Polyaromatische verbindungen zur behandlung von herpes-infektionen
ATE184598T1 (de) Enniatine und enniatinderivate zur bekämpfung von endoparasiten
LV12719A (lv) Benzoxazinones as inhibitors of hiv reverse transcriptase
PT705100E (pt) Guanidinas substituidas terapeuticas
MX9203972A (es) Compuestos inhibidores de la proteasa codificada por el virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulado farmaceutico que los contiene.
ES2183817T3 (es) Inibidores de proteasas de parasatiso metazoarios.
MX9303572A (es) Inhibidores de proteasa del sindrome de inmunodeficiencia humana, procedimiento para su preparacion y formualcion farmaceutica que los contiene.
DE69909747D1 (de) Pharmazeutische zusammensetzung, enthaltend peg-asparaginase, für die behandlung von hiv infektionen
MX9302681A (es) Nuevas quinazolinas como inhibidores de transcriptasa inversa hiv.
NO993627L (no) Anvendelse av en forbindelse for fremstilling av et legemiddel
CA2100066A1 (en) Michellamines useful as antiviral agents, composition and method of treatment
ES2096874T3 (es) Inhibidor de la proteasa de hiv util para el tratamiento del sida.
ES2159287T3 (es) Peptidos hemorreguladores.
MX9700414A (es) Agentes antivirales de difluoroestatona.